Ziprasidone
- Generic Name
- Ziprasidone
- Brand Names
- Geodon, Zeldox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H21ClN4OS
- CAS Number
- 146939-27-7
- Unique Ingredient Identifier
- 6UKA5VEJ6X
- Background
Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior. These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers. Luckily, several treatment options for psychotic disorders have been ...
- Indication
In its oral form, ziprasidone is approved for the treatment of schizophrenia, as monotherapy for acute treatment of manic or mixed episodes related to bipolar I disorder, and as adjunctive therapy to lithium or valproate for maintenance treatment of bipolar I disorder. The injectable formulation is approved only for treatment of acute agitation in schizophre...
- Associated Conditions
- Acute Agitation, Agitation, Bipolar 1 Disorder, Psychosis, Schizophrenia, Treatment Resistant Major Depressive Disorder, Acute Manic episode, Acute Mixed manic depressive episode
- Associated Therapies
- -
Four Interventions in the Management of Psychomotor Agitation, Safety and Efficacy Evaluation
- Conditions
- Interventions
- First Posted Date
- 2011-12-05
- Last Posted Date
- 2011-12-05
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 120
- Registration Number
- NCT01485692
- Locations
- 🇧🇷
Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto, USP, Ribeirão Preto, São Paulo, Brazil
Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder (Zip Ad)
- First Posted Date
- 2011-02-11
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT01293825
- Locations
- 🇺🇸
University Hospitals Case Medical Center, Cleveland, Ohio, United States
The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study
- Conditions
- Interventions
- First Posted Date
- 2010-09-29
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 566
- Registration Number
- NCT01211522
- Locations
- 🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States
🇺🇸University of Washington, Seattle, Washington, United States
🇺🇸Denver Health/University of Colorado Health Sciences Center, Denver, Colorado, United States
Effectiveness of Ziprasidone for Patients With Schizophrenia
- First Posted Date
- 2010-09-10
- Last Posted Date
- 2014-11-19
- Lead Sponsor
- Soonchunhyang University Hospital
- Target Recruit Count
- 67
- Registration Number
- NCT01198353
- Locations
- 🇰🇷
Korea University Medical Center Guro Hospital, Seoul, Korea, Republic of
🇰🇷Soonchunhyang University Bucheon Hospital, Bucheon, Korea, Republic of
🇰🇷Korea University Medical Center Ansan Hospital, Ansan, Gyeonggi-do, Korea, Republic of
Antipsychotics and Gene Expression in Soft Tissues
- Conditions
- Interventions
- First Posted Date
- 2010-08-20
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 16
- Registration Number
- NCT01185743
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)
- Conditions
- Interventions
- First Posted Date
- 2010-07-30
- Last Posted Date
- 2012-03-19
- Lead Sponsor
- VA Palo Alto Health Care System
- Target Recruit Count
- 49
- Registration Number
- NCT01172652
- Locations
- 🇺🇸
Lindner Center of Hope University of Cincinnati Medical Center, Mason, Ohio, United States
🇺🇸University of South Florida Institute for Research in Psychiatry, Tampa, Florida, United States
🇺🇸VA Palo Alto Health Care System & Stanford School of Medicine, Palo Alto, California, United States
Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder
- First Posted Date
- 2010-07-23
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Tufts Medical Center
- Target Recruit Count
- 49
- Registration Number
- NCT01168674
Efficacy and Safety With Ziprasidone in First-episode Psychosis
- Conditions
- First Posted Date
- 2010-07-07
- Last Posted Date
- 2010-07-07
- Lead Sponsor
- Chonbuk National University Hospital
- Target Recruit Count
- 27
- Registration Number
- NCT01157559
- Locations
- 🇰🇷
Heo psychiatric Hospital, Jeonju, Korea, Republic of
🇰🇷Jeonju Jesus Hospital, Jeonju, Korea, Republic of
🇰🇷Department of Psychiatry, Chonbuk national University Hospital, Jeonju, Korea, Republic of
A Non-Interventional Post-Marketing Surveillance Study to Evaluate the Safety and Efficacy of Zeldox Capsule
- First Posted Date
- 2010-01-21
- Last Posted Date
- 2021-03-03
- Target Recruit Count
- 3391
- Registration Number
- NCT01053429
Ziprasidone in Early Onset Schizophrenia Spectrum Disorders
- First Posted Date
- 2009-11-03
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 40
- Registration Number
- NCT01006551
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸Harvard University, Medford, Massachusetts, United States
🇺🇸University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.